COVID-19: Joint statement from ECDC and EMA on the administration of a fourth dose of mRNA vaccines

According to a Press release on the 6 April,  EMA’s COVID-19 task force (ETF) and the European Centre for Disease Prevention and Control (ECDC) have reviewed currently available studies and epidemiological data to provide a common position for EU/EEA countries on the current need and potential benefit of a fourth dose (second booster dose) of mRNA COVID-19 vaccines.

Administration of a fourth dose of mRNA vaccine to immunocompromised individuals whose immune systems may have responded sub optimally to previous vaccination is already recommended and should be part of current vaccination campaigns. Currently, there are no data on the immunogenicity, safety, or efficacy of additional further doses in this population. In addition, passive immunization with monoclonal antibodies should be considered for severely immunocompromised individuals as additional protection against infection and disease.

If you would like to contact us send an email at : [email protected]